Circulating immune biomarkers in peripheral blood correlate with clinical outcomes in advanced breast cancer

par Natalia Palazón-Carrión, Carlos Jiménez-Cortegana, M. Luisa Sánchez-León, Fernando Henao-Carrasco, Esteban Nogales-Fernández, Massimo Chiesa, Rosalía Caballero, Federico Rojo, María-Adoración Nieto-García, Víctor Sánchez-Margalet, Luis de la Cruz-Merino, the Spanish Breast Cancer Group (GEICAM) and the Spanish Group for Immunobiotherapy of Cancer (GÉTICA)
Publié 2021

Publisher Correction: Circulating immune biomarkers in peripheral blood correlate with clinical outcomes in advanced breast cancer

par Natalia Palazón‑Carrión, Carlos Jiménez‑Cortegana, M. Luisa Sánchez‑León, Fernando Henao‑Carrasco, Esteban Nogales‑Fernández, Massimo Chiesa, Rosalía Caballero, Federico Rojo, María‑Adoración Nieto‑García, Víctor Sánchez‑Margalet, Luis de la Cruz‑Merino, the Spanish Breast Cancer Group (GEICAM) and the Spanish Group for Immunobiotherapy of Cancer (GÉTICA)
Publié 2021

Pembrolizumab Plus Gemcitabine in the Subset of Triple-Negative Advanced Breast Cancer Patients in the GEICAM/2015-04 (PANGEA-Breast) Study

par Luis de la Cruz-Merino, María Gion, Josefina Cruz-Jurado, Vanesa Quiroga, Raquel Andrés, Fernando Moreno, Jose L. Alonso-Romero, Manuel Ramos, Esther Holgado, Javier Cortés, Elena López-Miranda, Fernando Henao-Carrasco, Natalia Palazón-Carrión, Luz M. Rodríguez, Isaac Ceballos, Maribel Casas, Sara Benito, Massimo Chiesa, Susana Bezares, Rosalia Caballero, Carlos Jiménez-Cortegana, Víctor Sánchez-Margalet, Federico Rojo
Publié 2021